Showing results (121-130 of 214) with videos related to

Sort By:
Pageof 22
British Journal of Cancer|January 1, 1997
A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancerN Siddiqui, A V Boddy, H D Thomas, et al.
Annals of Neurology|July 29, 2005
Complement inhibition abrogates nerve terminal injury in Miller Fisher syndromeSusan K Halstead, Peter D Humphreys, John A Goodfellow, et al.
Advances in Enzyme Regulation|January 1, 1991
Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8-dideazafolatesA L Jackman, P R Marsham, R G Moran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitroE Marshman, D R Newell, A H Calvert, et al.
European Journal of Cancer & Clinical Oncology|April 1, 1988
Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancerB M Cantwell, V Macaulay, A L Harris, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)D L Alison, D R Newell, C Sessa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)M A Batey, J G Wright, A Azzabi, et al.
British Journal of Cancer|November 1, 1991
The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in miceD I Jodrell, D R Newell, S E Morgan, et al.
Glia|June 22, 2005
Anti-disialosyl antibodies mediate selective neuronal or Schwann cell injury at mouse neuromuscular junctionsSusan K Halstead, Ian Morrison, Graham M O'Hanlon, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalationB J Foster, D R Newell, M A Graham, et al.
Pageof 22